Abstract:We aimed to investigate the diagnostic and prognostic value of 68Ga-pentixafor PET/CT imaging in noncancer patients with suspected adrenal masses. Methods: Sixty-four patients who had benign adrenal masses on CT were retrospectively included in our study. All patients underwent 68Ga-pentixafor PET/CT, and 56 of these patients subsequently underwent adrenalectomy. The subtypes of 81 adrenal tumors, including 14 nonfunctioning adrenal nodules, 4 cortisol-producing adenomas, 41 aldosterone-producing adenomas, 5 cases of suspected unilateral adrenal hyperplasia, 15 cases of idiopathic aldosterone hyperplasia, and 2 pheochromocytomas, were determined by histology or follow-up evaluations. The diagnostic efficiency of functional lateralization was calculated by visual analysis. Semiquantitative parameters of these lesions, including SUVmax, the ratio of lesional SUVmax to normal liver SUVmean (LLR), and the ratio of lesional SUVmax to contralateral adrenal tissue SUVmean (LCR), were also calculated. Dynamic analysis was also performed on 15 patients. In addition, clinical outcomes were assessed and compared in patients who underwent adrenalectomy. Results: The sensitivity and specificity of 68Ga-pentixafor PET for functional lateralization in patients with adrenocortical lesions were 97.8% (45/46) and 87.5% (14/16), respectively. The 2 pheochromocytoma lesions had lower pentixafor uptake than the normal adrenal glands. Functioning (active) adrenocortical adenomas showed an elevated SUVmax of 16.3 ± 7.9, in comparison to 4.4 ± 1.7 in nonfunctioning (inactive) adenomas and 5.5 ± 2.7 in hyperplasia lesions (P < 0.0001). To identify active adrenocortical adenomas, a cutoff of 7.1 for SUVmax showed a sensitivity of 90.9% and a specificity of 85.3% (area under receiver-operating-characteristic curve, 0.96; P < 0.0001); a cutoff of 2.5 for LLR showed a sensitivity of 95.5% and a specificity of 88.2% (area under receiver-operating-characteristic curve, 0.97; P < 0.0001); and a cutoff of 2.4 for LCR showed a sensitivity of 88.6% and a specificity of 91.8% (area under receiver-operating-characteristic curve, 0.95; P < 0.0001). The graphical influx rate constant of active adrenocortical adenomas was significantly higher than that of inactive adenomas. Uptake values for 68Ga-pentixafor were significantly higher in patients with preferable outcomes (cured/improved) (SUVmax, 15.5 ± 8.0; LLR, 6.5 ± 4.3; LCR, 6.2 ± 5.0) than in patients with nonpreferable outcomes (no improvement) (SUVmax, 4.2 ± 0.5; LLR, 1.3 ± 0.2; LCR, 1.5 ± 0.6; all P < 0.0001). Conclusion:68Ga-pentixafor PET/CT imaging exhibits great potential for noninvasive functional lateralization and characterization in patients with adrenocortical masses.

[18F]FDG-PET/CT in adrenal lesions: diagnostic performance in different clinical settings

Current generation time-of-flight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands

18F-fluorodeoxyglucose positron emission tomography/computed tomography as an effective diagnostic workup in cervical metastasis of carcinoma from an unknown primary tumor

The role of F-18-FDG PET/CT in the management of bilateral adrenal gland lesions

18F-FDG PET Imaging for Differentiating Malignant from Benign Lesions in Patients with Adrenal Masses

[18F]FDG PET/CT and PET/MR in Patients with Adrenal Lymphoma: A Systematic Review of Literature and a Collection of Cases

Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using 68Ga-Pentixafor.

Prognostic value of [18F]FDG PET/CT parameters in surgically resected primary lung adenocarcinoma: a single-center experience

SUVmax of 18FDG PET/CT Predicts Histological Grade of Lung Adenocarcinoma

Challenging the significance of SUV-based parameters in a large-scale retrospective study on lung lesions

Is It Possible to Establish a Reliable Correlation between Maximum Standardized Uptake Value of 18-Fluorine Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and Histological Types of Non-Small Cell Lung Cancer? Analysis of the Italian VATS Group Database

Value of 18F?FDG PET/CT in Differentiation of Noninvasive and Malignant Pancreatic Cystic Lesions

The Utility of 18F-FDG PET/CT for the Diagnosis of Adrenal Metastasis in Lung Cancer: a PRISMA-compliant Meta-Analysis

18 F-FAPI PET/CT Performs Better in Evaluating Mediastinal and Hilar Lymph Nodes in Patients with Lung Cancer: Comparison with 18 F-FDG PET/CT

Value of fluorine-18-fluorodeoxyglucose PET/CT in localizing the primary lesion in adrenocorticotropic hormone-dependent Cushing syndrome.

Differential Diagnostic Value of 18F-FDG PET/CT in Osteolytic Lesions.

Role of SUVmax Obtained by 18F-FDG PET/CT in Patients with a Solitary Pancreatic Lesion

Use of 18F-FDG-PET/CT for Retroperitoneal/Intra-Abdominal Soft Tissue Sarcomas

Correlation between degree of malignancy of pheochromocytoma and standardized uptake value (SUV) measured by 18F-FDG PET/CT

Clinical use of 18F-FDG PET/CT in the differential diagnosis of patients with primary and secondary adenoid cystic carcinoma of the lung: a retrospective cohort study

Diagnostic ability of [18F]FDG PET/CT for distinguishing benign from malignant spleen lesions